AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 64 min read$PGNY

Progyny’s (NASDAQ:PGNY) Q2 CY2026: Beats On Revenue But Stock Drops 10.2%

Progyny (NASDAQ:PGNY) reported Q2 CY2026 revenue of $350.5 million, up 5.3% year on year and 0.6% above analysts’ estimates. Non-GAAP EPS was $0.55, 6.2% above consensus. For next quarter, it guided revenue to $340 million, about 3% below estimates. Shares fell 10.2% to $27.08 after the release.

Original reporting
financialcontent.com
Published Aug 6, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Progyny’s (NASDAQ:PGNY) Q2 CY2026: Beats On Revenue But Stock Drops 10.2% — source image
Source · financialcontent.com
Decision brief

The 30-second read

$PGNYBearishMed
01

Why it matters

Traders likely focused on the forward revenue guide ($340M) and the mention that EBITDA guidance fell short, which outweighed the Q2 revenue and adjusted EPS beats.

02

Market read

This is a classic earnings reaction setup: headline beats, but forward guidance disappointment triggers a large single-day decline.

03

What to watch

The article notes member engagement trending toward the higher end of expectations and that unit growth lagged revenue, implying pricing mix may support margins even if near-term guidance softens.

Relevance 8/10Novelty 6/10Timing: after-hours/next-session reaction to Q2 results and next-quarter guidance

Background

Progyny is a fertility benefits provider using a data-driven model to deliver fertility treatments and support services to employer members.

Company-level read

Ticker impact

$PGNYBearishHigh confidence
Context

Progyny reported Q2 CY2026 revenue of $350.5M (beat) but guided next-quarter revenue to $340M (below estimates), with the stock down 10.2% to $27.08.

Expected impact

Near-term downside bias as traders reprice the next-quarter revenue and EBITDA shortfall versus consensus.

Evidence & confidence

The article provides specific Q2 results, next-quarter revenue guidance below estimates, and a same-day 10.2% drop, indicating guidance sensitivity dominates the reaction.

Market effects

Sector

Highlights how fertility-benefits managed-care names can trade more on forward guidance than on single-quarter beats.

Regional

Limited, company-specific move in US healthcare/benefits space.

Global

Low, no cross-border deal or regulatory action mentioned.

Counterpoint

What could challenge this read

The revenue and adjusted EPS beats suggest underlying demand remains intact; the guidance miss could be timing-related rather than a durable slowdown.

Key entities

  • company
    Progyny

    Fertility benefits company reporting Q2 CY2026 results and issuing next-quarter revenue guidance.

  • executive
    Pete Anevski

    CEO quoted on member engagement trends reflecting demand for fertility services.

Read at source← All news

Related articles

AUG 7
$PGNYMedAI 8/10

Why Progyny (PGNY) Shares Are Sliding Today

Progyny (PGNY) shares fell about 4.5% after the fertility benefits company issued weaker guidance. Q2 revenue rose to $350.5M (+5.3% YoY) and adjusted EPS was $0.55, both above estimates. But it projected $340M revenue for the next quarter, about 3% below consensus, and cut full-year revenue to $1.37B from $1.39B.

financialcontent.com5 min
AUG 7
$PGNYMed

Why Progyny Stock Plunged, Then Gradually Recovered Today

Progyny (PGNY) shares fell about 6% after its Q2 earnings. The company reported 5% sales growth, with adjusted EPS up 15% versus expectations. Q3 sales guidance calls for 7% to 11% growth and adjusted earnings are slightly lower sequentially. Gross margins rose 180 bps and covered members increased 7% to 7.2 million.

yahoo.com3 min
AUG 6
$PGNYMed

Progyny, Inc. (PGNY): Results of Operations and Financial Condition

Progyny, Inc. (PGNY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026.htm EX-99.1 Document Progyny, Inc. Announces Second Quarter 2026 Results Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDA Robust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building Solutions V

SEC EDGAR 8-K4 min
JUL 13
$PGNYMed

Progyny (PGNY) Stock Is Up, What You Need To Know

Progyny (PGNY) shares rose 3.5% to $31.73 after KeyBanc raised its price target to $35 from $30 and kept an Overweight rating, citing expectations for a strong earnings report and higher future guidance. The article also notes other bullish analyst actions, including Truist raising its target and Canaccord upgrading to Buy.

financialcontent.com4 min
MAY 31
$PGNYMedAI 8/10

A Progyny (PGNY) Insider Sold 5,500 Shares for $137,000

Progeny (PGNY) director Kevin Gordon sold 5,500 shares for about $137,000, according to the article. The firm reported Q1 revenue of $328 million, up 1.4% YoY, with gross profit rising 10% to $83.1 million. It said client growth and retention were strong aside from a large client loss, and approved a $200 million share repurchase program.

finance.yahoo.com5 min
MAY 26
$PGNYMedAI 8/10

Progyny, Inc. Announces Share Repurchase Program

Progyny, Inc. (Nasdaq: PGNY) said its board approved a share repurchase program to buy back up to $200 million of common stock, funded from available cash. Repurchases may be made via open-market transactions, including Rule 10b5-1 plans, and can be suspended or ended anytime, according to the company.

manilatimes.net1 min